SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT04006249

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Haemochromatosis and Periodontitis

Periodontitis is a chronic inflammatory disease that affects tissues surrounding the teeth. It is strongly associated with the major pathogenic "red complex", including Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola1 and thus is considered an infection. Recent advances in the pathogenesis of periodontal disease have suggested that polymicrobial synergy and microbiota dysbiosis together with a dysregulated immune response can induce inflammation-mediated damage in periodontal tissues2-4. Interestingly, currently periodontitis is associated with a growing number of systemic diseases, including cardiovascular diseases, adverse pregnancy outcomes, diabetes5-7 and hereditary haemochromatosis8.

NCT04006249 to Evaluate the Prevalence of Periodontal Diseases in Patients With Hemochromatosis at the Time of Diagnosis and / or Their Usual Therapeutic
MeSH: Periodontitis Periodontal Diseases Hemochromatosis
HPO: Periodontitis

1 Interventions

Name: dental probes

Description: Measurement of the depth of the periodontal pockets and clinical loss

Type: Diagnostic Test

diagnostic test


Primary Outcomes

Description: To evaluate the prevalence of periodontal diseases in patients with hemochromatosis at the time of diagnosis and / or their usual therapeutic

Measure: prevalence of periodontal diseases

Time: 2 years

Purpose: Diagnostic

Single Group Assignment


There is one SNP

SNPs


1 C282Y

Inclusion Criteria: - Patients aged 35 to 64 years with homozygosity hemochromatosis C282Y - Patients regularly enrolled in a health insurance plan - Patients with at least 10 natural teeth - Patients who have given informed written, dated and signed consent Exclusion Criteria: - Diabetic patients - Simultaneous participation in another study - Pregnant or lactating women - The incapacitated persons and persons deprived of their liberty - Patients who do not speak French, both written and spoken - Patients previously included in this trial - Patients with heart valves or endovascular equipment (risk of infective endocarditis ...) - Patients with a history of maxillofacial surgery - Patients whose oral status is considered incompatible with entry into the study, at the discretion of the investigator - Patients on drugs that can cause gingival hypertrophy, such as Hydantoins (phenytoin), Dihydropyridines, Diltiazem or Ciclosporin - Patients on medication that can cause gingival bleeding (anticoagulants, antiplatelet agents and aspirin). --- C282Y ---



HPO Nodes


HPO:
Periodontitis
Genes 31
COL3A1 ELANE DKC1 TCIRG1 FGF3 COL5A1 SRP54 C1R C1S PARN NOP10 OCRL PLG WRAP53 AP3B1 USB1 NHP2 TERC TINF2 RTEL1 TERT CTC1 ITGB2 LYST CXCR4 SLC35C1 GFI1 CTSC NOTCH2 GORAB FERMT1